Press Releases

Vivoryon Therapeutics Reports Third Quarter 2019

HALLE (SAALE), Germany, 28 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE0007921835), announced today its third quarter business update for the period ending September […]

Vivoryon Therapeutics attends CTAD 2019

HALLE (SAALE), Germany, 27 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE0007921835), announced today that management of Vivoryon Therapeutics will attend the CTAD […]

Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019

HALLE (SAALE), Germany, 21 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), will publish its third quarter financial results and a business update for the period […]

Vivoryon Therapeutics to Attend and Present at Investor Conferences in November 2019

HALLE (SAALE), Germany, 4 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), announced today that the company is scheduled to attend and present at upcoming conferences […]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS RELEASE.

Vivoryon Therapeutics AG Successfully Completes a EUR 43 Million Capital Raise                            HALLE (SAALE), Germany, 24 October 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN: DE0007921835, […]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS RELEASE.

Vivoryon Therapeutics AG Launches Rights Offering to Fund its Phase 2b Clinical Development Program in Alzheimer’s Disease with Strong Commitments                            HALLE (SAALE), Germany, 08 October […]

Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update

Conference call and webcast in English at 3:00 pm CEST / 09:00 am EST Successful private placement of EUR 8.2 million Strategic collaboration with MorphoSys announced in July […]

Vivoryon Therapeutics AG to Publish its Half Year 2019 Results on August 29, 2019

HALLE (SAALE), Germany, 22 August 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), will publish its Half Year Results for 2019 on Thursday, August 29, 2019. The […]

MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology

HALLE (SAALE) and PLANEGG/MUNICH Germany, 8 July 2019: Vivoryon Therapeutics AG (Euronext Amsterdam: VVY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: […]

Vivoryon Therapeutics AG enters myeloid immune checkpoint drug discovery, and collaborates with the University of Kiel to select cancer therapy candidates from its QPCTL inhibitor portfolio

HALLE (SAALE), Germany, 27 June 2019 – Vivoryon Therapeutics AG, (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835) announced today that they have […]

Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology  

HALLE (SAALE) and MUNICH, Germany, 18 June 2019 – Vivoryon Therapeutics AG, (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835), a clinical stage precision […]

Probiodrug AG becomes Vivoryon Therapeutics AG

Healthy Aging – Pioneering Innovation HALLE (SAALE), Germany, 12 June 2019 – Probiodrug AG (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835), focusing on […]

Ordinary General Meeting of Shareholders of Probiodrug AG

All proposed resolutions approved with large majority   HALLE (SAALE), Germany, 29 May 2019 – Probiodrug AG (Euronext Amsterdam: PBD), announces that its shareholders approved all resolutions […]

Probiodrug to attend International Conferences in June 2019

HALLE (SAALE), Germany, 22 May 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), announces that the company is scheduled to attend the following conferences:   (1) 2019 BIO […]

Probiodrug Reports First Quarter 2019 Business Update

HALLE (SAALE), Germany, 16 May 2019 – Probiodrug AG (Euronext Amsterdam: PBD), announced today its first quarter business update for the period ending March 31, 2019.   The […]

Probiodrug AG to Publish its First Quarter 2019 Business Update on May 16, 2019

HALLE (SAALE), Germany, 9 May 2019 – Probiodrug AG (Euronext Amsterdam: PBD, ISIN: DE0007921835), is focusing on the discovery and development of drugs acting on enzymes which […]

Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 29 May 2019

HALLE (SAALE), Germany, 18 April 2019 – Probiodrug AG (Euronext Amsterdam: PBD; ISIN: DE0007921835), invites all shareholders to Probiodrugs ordinary general meeting of shareholders to be […]

Probiodrug raises EUR 8.2 million in successful private placement of new shares

Consortium of strategic investors led by Dr. Claus Christiansen founder and chairman of the board of Nordic Bioscience, Denmark, invests EUR 6.2 million Proceeds used to […]

Probiodrug raises EUR 8.2 million from investors in successful private placement of new shares

NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA   Probiodrug raises EUR 8.2 million from investors in successful private […]

Probiodrug AG has mandated ODDO SEYDLER BANK AG as Designated Sponsor

The shares are trading on XETRA, the electronic trading platform of Deutsche Börse.     HALLE (SAALE), Germany, 04 APRIL 2019 – Shares in Probiodrug AG, (Euronext […]

Probiodrug reports full year 2018 financial results

Conference call and webcast (in English) at 3:00 pm CET (10:00 am EDT) NIH grant of 15million USD received PQ912 Phase 2b core program prepared   HALLE (SAALE), […]

Probiodrug AG to Publish its Full Year 2018 Results on March 28, 2019

HALLE (SAALE), Germany, 21 March 2019 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish […]

Probiodrug and Alzheimer’s Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912

Study to Evaluate Safety and Efficacy of Drug Seeking to Treat Those with Mild Cognitive Impairment or Mild Dementia   HALLE (SAALE), Germany and San Diego, […]

Probiodrug to attend BIO Europe Spring in March 2019

HALLE (SAALE), Germany, 12 March 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug to attend International Conferences in February 2019

HALLE (SAALE), Germany, 5 February 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug to attend at J.P. Morgan Healthcare Conference in January 2019

HALLE (SAALE), Germany, 18 December 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug to present at Antibody Engineering & Therapeutics in December 2018

HALLE (SAALE), Germany, 04 December 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug AG Reports Third Quarter 2018 Business Update

HALLE (SAALE), Germany, 29 November 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]

Probiodrug AG to Publish its Third Quarter 2018 Business Update on November 29, 2018

Probiodrug AG to Publish its Third Quarter 2018 Business Update on November 29, 2018     HALLE (SAALE), Germany, 22 November 2018 – Probiodrug AG (Euronext […]

Probiodrug to Attend and Present at International Conferences in November 2018

HALLE (SAALE), Germany, 29 October, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug publishes SAPHIR data in peer reviewed journal

SAPHIR trial data published in Alzheimer’s Research & Therapy   HALLE (SAALE), Germany, 16 October 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company […]

Probiodrug AG: Loss announcement according to §92 paragraph 1 of the German Stock Corporation Act

HALLE (SAALE), Germany, 15 October 2018 – The management board of Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to […]

Probiodrug to attend International Conferences in October 2018

HALLE (SAALE), Germany, 09 October, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug Reports Management Changes

HALLE (SAALE), Germany, October 5th, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announced today […]

Probiodrug Appoints Dr. Michael Schaeffer as Executive Vice President of Business and Strategy

HALLE (SAALE), Germany, 04 September, 2018: Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today […]

Probiodrug Reports Financial Results for H1 2018 and Corporate Update

HALLE (SAALE), Germany, 30 August 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]

Probiodrug AG to Publish First Half 2018 Results on August 30, 2018

HALLE (SAALE), Germany, 23 August 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]

Ordinary General Meeting of Shareholders of Probiodrug AG

All proposed resolutions approved with large majority   HALLE (SAALE), Germany, 22 June 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel […]

Probiodrug to attend and present at the BIO International Convention in June 2018

HALLE (SAALE), Germany, 29 May 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug updated Privacy Policy

HALLE (SAALE), Germany, 25 May 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces today […]

Probiodrug AG reports First Quarter 2018 Business Update

HALLE (SAALE), Germany, 15 May 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today […]

Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 21 June 2018

HALLE (SAALE), Germany, 09 May 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), has […]

Probiodrug positioning its pGlu-Abeta Antibody in the field of Abeta antibodies

Probiodrug co-authored a review paper entitled “Passive Aβ Immunotherapy: Current Achievements and Future Perspectives “     HALLE (SAALE), Germany, 08 May 2018 Probiodrug AG (Euronext […]

Probiodrug AG to Publish its First Quarter 2018 Business Update on 15 May 2018

HALLE (SAALE), Germany, 8 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will […]

Probiodrug to attend and present at International Conferences in May 2018

HALLE (SAALE), Germany, 04 May 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug Appoints Dr. Ulrich Dauer as Chief Executive Officer

Dr. Ulrich Dauer to team up with Chief Development Officer, Dr. Inge Lues, effective May 1, 2018; Dr. Konrad Glund and Dr. Hendrik Liebers to continue […]

Probiodrug to attend and present at International Conferences in April 2018

HALLE (SAALE), Germany, 10 April 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug reports full year 2017 financial results

PQ912 delivers positive pharmacodynamic and efficacy results in a Phase 2a study in early stage AD patients – data presented at CTAD, Boston, November 2017 PQ912 Phase […]

Probiodrug AG to Publish its Full Year 2017 Results on 3 April 2018

HALLE (SAALE), Germany, 27 March 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish […]

Probiodrug to present at 255th ACS National Meeting & Exposition

The Inhibition of Glutaminyl Cyclase as a New Concept for the Treatment of Alzheimer’s Disease: PQ912, the First-In-Class QC-Inhibitor in Clinical Development for AD   HALLE […]

Probiodrug to attend and present at International Conferences in March 2018

HALLE (SAALE), Germany, 27 February 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug to attend and present at upcoming international conferences

HALLE (SAALE), Germany, 23 January 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug to attend and present at international conferences in January 2018

HALLE (SAALE), Germany, 14 December 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug and Crossbeta Biosciences extend their strategic partnership in the field of Alzheimer’s disease biomarkers

HALLE (SAALE), Germany, UTRECHT, The Netherlands, 5 December 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease […]

Probiodrug reports Third Quarter 2017 Business Update

HALLE (SAALE), Germany, 30 November 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]

Probiodrug AG to Publish its Third Quarter 2017 Business Update on 30 November 2017

HALLE (SAALE), Germany, 23 November 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]

Probiodrug to Present Data from its Phase 2a SAPHIR Study at International Alzheimer’s Disease Conference

Prof. Philipp Scheltens, Principal Investigator of the study, to present at Clinical Trials on Alzheimer’s Disease (CTAD) 2017 in Boston   Management will host a conference […]

Probiodrug to present at Life Sciences Conferences in November

HALLE (SAALE), Germany, 24 October 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug initiates Phase 2b core program of PQ912 and details further strategy

Company moves seamlessly from finalization of the SAPHIR Phase 2a to next clinical stage Probiodrug takes a double-pronged strategy – starts operational preparation of clinical studies […]

Probiodrug to present at Life Sciences Conferences in October 2017

HALLE (SAALE), Germany, 28 September 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug reports financial results for H1 2017 and corporate update

PQ912 delivers positive pharmacodynamic and efficacy results in a Phase-2a study  in early stage AD patients Successful settlement of longpending tax issue PQ912 demonstrates efficacy in […]

Probiodrug to present and attend at International Conferences in September 2017

HALLE (SAALE), Germany, 30 August 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Unique binding mode of PBD-C06 to pGlu-Abeta peptides identified

Probiodrug publishes mechanism of target binding for its lead anti-pGlu-Abeta monoclonal antibody PBD-C06     HALLE (SAALE), Germany, 29 August 2017 – Probiodrug AG (Euronext Amsterdam: PBD), […]

Probiodrug AG to Publish First Half 2017 Results on 31 August 2017

HALLE (SAALE), Germany, 24 August 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its results […]

Ordinary General Meeting of Shareholders of Probiodrug AG

All proposed resolutions approved with large majority   HALLE (SAALE), Germany, 14 June 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions […]

Probiodrug announces encouraging results of the Phase 2a SAPHIR Study

HALLE (SAALE), Germany, 11 June 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced […]

Probiodrug to present and attend at International Conferences in June 2017

HALLE (SAALE), Germany, 30 May 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug AG Announces Acceptance of PQ912 Pharmacology Paper by Peer Reviewed Journal

HALLE (SAALE), Germany, 16 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]

Probiodrug AG reports First Quarter 2017 Business Update

HALLE (SAALE), Germany, 12 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]

Probiodrug AG to Publish its First Quarter 2017 Business Update on 12 May 2017

HALLE (SAALE), Germany, 5 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]

Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 13 June 2017

HALLE (SAALE), Germany, 02 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), has the honour […]

Probiodrug to attend an present at International Conferences in May 2017

HALLE (SAALE), Germany, 25 April 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug to present at Huntington’s Disease Therapeutics Conference

The Glutaminyl Cyclase (QC) inhibitor PQ912 demonstrates beneficial effects in a preclinical Huntington´s disease model   HALLE (SAALE), Germany, 10 April 2017 – Probiodrug AG (Euronext […]

Last Patient Last Visit (LPLV) reached in the SAPHIR Study

Last Patient Last Visit (LPLV) reached in the SAPHIR Study, a Phase 2 trial with the Glutaminyl Cyclase (QC) inhibitor PQ912 in early Alzheimer’s Disease (AD) […]

Probiodrug to attend International Conferences in April 2017

HALLE (SAALE), Germany, 03 April 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug reports full year 2016 financial results

SAPHIR, the Phase 2a study of PQ912 as a novel treatment for Alzheimer’s disease fully enrolled Favourable results of chronic toxicology studies with PQ912 announced Promising […]

Probiodrug to present at Alzheimer’s and Parkinson’s Diseases Congress

New results of a double pronged-approach to target the neurotoxic amyloid beta species pGlu-Abeta, and an evaluation of new biomarkers in cerebrospinal fluid (CSF) from AD […]

Probiodrug AG to Publish its Full Year 2016 Results on 30 March 2017

HALLE (SAALE), Germany, 23 March 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its Full […]

Probiodrug to attend and present at International Conferences in March 2017

HALLE (SAALE), Germany, 06 March 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]